Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Interest Income
Income earned on cash, deposits, and investments held by the company.
Mereo BioPharma Group plcNASDAQ: MREO
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $326.45K fell 50.5% year over year, behind the -40.4% change in trailing-twelve-month interest income. Sequentially, it fell 22.5% from the prior quarter. Over 3 fiscal years it compounded at +46.2% a year.
Context
- Interest income amounted to 434.6% of revenue in FY2025.
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -50.5% toward the trailing-twelve-month pace of -40.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 2.17M USD
- Year-over-year change
- -28.6%
- 4-year CAGR
- +530.5%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.17M | -28.6% |
| FY2024 | 2024-12-31 | 3.04M | +42.8% |
| FY2023 | 2023-12-31 | 2.13M | +206.2% |
| FY2022 | 2022-12-31 | 696K | +50518.2% |
| FY2021 | 2021-12-31 | 1.38K | — |
Interest Income vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -40.4% is the 6th highest of 10, against a peer median of -10.7%.
- Interest income amounts to 367.5% of revenue for MREO, versus a peer median of 21.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.6M USD | -44.4% | +152.5% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $8.5M USD | -10.7% | +121.3% | — |
| LTM Mar 2026 | $8.43M USD | +242.7% | +128.9% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $7.09M USD | -0.4% | +66.6% | — |
| FY2025 | A$5.25M AUD | +35.2% | +186.0% | 104.1% | |
| LTM Mar 2026 | $4.3M USD | +153.1% | +47.6% | — | |
| LTM Mar 2026 | $2.91M USD | -45.8% | +12.3% | — | |
| LTM Mar 2026 | $1.84M USD | -40.4% | +46.2% | 367.5% | |
| LTM Mar 2026 | CHF 1.36M CHF | -58.3% | +200.1% | 36.6% | |
| LTM Mar 2026 | €852.58K EUR | -60.2% | +176.5% | 6.3% | |
| LTM Mar 2026 | $0 USD | — | +148.8% | 0.0% | |
| Peer median (excluding MREO) | — | -10.7% | +138.9% | 21.5% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.21M | 0 | 10M | 0 | 500K |
| Cost of Revenue | 24.17M | (257.44K) | 2.57M | 1.09M | 133K |
| Gross Profit | 25.04M | 257.44K | 7.43M | (1.09M) | 367K |
| Gross Margin | 50.9% | — | 74.3% | — | 73.4% |
| Research & Development | 31.8M | 30.75M | 17.42M | 20.93M | 17.77M |
| Selling, General & Admin | 21.5M | 23.18M | 18.42M | 26.43M | 23.01M |
| Operating Expenses | 53.3M | 53.92M | 35.84M | 47.36M | 38.62M |
| Depreciation & Amortization | 866.47K | 895.5K | 1.06M | 1.09M | 1.15M |
| EBITDA | 25.49M | (39.98M) | (26.06M) | (40.8M) | (40.47M) |
| EBITDA Margin | 51.8% | — | -260.6% | — | -8094.8% |
| Operating Income | (28.26M) | (53.67M) | (28.42M) | (47.36M) | (38.26M) |
| Operating Margin | -57.4% | — | -284.2% | — | -7651.4% |
| Interest Income | 1.38K | 696K | 2.13M | 3.04M | 2.17M |
| Interest Expense | 5.22M | 3.36M | 2.88M | 1.37M | 255K |
| Other Income / Expenses | 47.48M | 9.21M | (1.58M) | 4.11M | (3.62M) |
| Income Before Tax | 19.22M | (44.46M) | (30M) | (43.25M) | (41.88M) |
| Pre-Tax Margin | 39.1% | — | -300.0% | — | -8375.6% |
| Income Tax Expense | 2.05M | (2.34M) | (532K) | 0 | 0 |
| Net Income | 17.17M | (42.12M) | (29.47M) | (43.25M) | (41.88M) |
| Net Margin | 34.9% | — | -294.7% | — | -8375.6% |
| EPS (Basic) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| EPS (Diluted) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| Weighted Avg Shares | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
| Weighted Avg Shares (Diluted) | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.